Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Hepatitis C, Chronic 2Virus Diseases 1Liver Diseases 1Hepatitis C 1Carcinoma, Hepatocellular 1

Interventions

halofantrine 2Sorafenib 2trifluridine tipiracil drug combination 1trametinib 1toripalimab 1tislelizumab 1sintilimab 1rubitecan 1repotrectinib 1pevonedistat 1pembrolizumab 1ozanimod 1lenvatinib 1ledipasvir, sofosbuvir drug combination 1gadolinium ethoxybenzyl DTPA 1fisogatinib 1ficlatuzumab 1camrelizumab 1belinostat 1avelumab 1Trabectedin 1Shadowing Technique, Histology 1Ramucirumab 1Patient Navigation 1Oxaliplatin 1Nutritional Status 1Nivolumab 1Nadroparin 1N-monoacetylcystine 1Magnetic Resonance Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Liver Diseases × ledipasvir, sofosbuvir drug combination × Clear all
NCT02868242 2020-03-02

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy

Gilead Sciences

Phase 2 Completed
19 enrolled 14 charts

Hepatitis C, Liver Diseases, Virus Diseases, Hepatitis C, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡